Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models

Niranjan Awasthi, Emily Scire, Sheena Monahan, Meghan Grojean, Eric Zhang, Margaret A. Schwarz, Roderich E. Schwarz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel response by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in preclinical PDAC models. In subcutaneous xenografts using AsPC-1 cells, average net tumor growth in different therapy groups was 248.3 mm3 in controls, 42.4 mm3 after nab-paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 0.01) and 1.9 mm3 after nab-paclitaxel plus BMS-754807 (p = 0.0002). In subcutaneous xenografts using Panc-1 cells, average net tumor growth in different therapy groups was: 294.3 mm3 in controls, 23.1 mm3 after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS- 754807 (p = 0.02) and -87.4 mm3 (tumor regression) after nab-paclitaxel plus BMS- 754807 (p = 0.0001). In peritoneal dissemination model using AsPC-1 cells, median animal survival was increased compared to controls (21 days) after therapy with nab-paclitaxel (40 days, a 90% increase, p = 0.002), BMS-754807 (27 days, a 29% increase, p = 0.01) and nab-paclitaxel plus BMS-754807 (47 days, a 124% increase, p = 0.005), respectively. Decrease in proliferation and increase in apoptosis by nabpaclitaxel and BMS-754807 therapy correlated with their in vivo antitumor activity. In vitro analysis revealed that the addition of IC25 dose of BMS-754807 decreased the nab-paclitaxel IC50 of PDAC cell lines. BMS-754807 therapy decreased phospho-IGF- 1R/IR and phospho-AKT expression, and increased cleavage of caspase-3 and PARP-1. These results support the potential of BMS-754807 in combination with nab-paclitaxel as an effective targeting option for pancreatic cancer therapy.

Original languageEnglish (US)
Pages (from-to)46988-47001
Number of pages14
JournalOncotarget
Volume7
Issue number30
DOIs
StatePublished - 2016

Fingerprint

Somatomedins
Pancreatic Neoplasms
Adenocarcinoma
Group Psychotherapy
Heterografts
Neoplasms
130-nm albumin-bound paclitaxel
Inhibition (Psychology)
BMS 754807
Therapeutics
Growth
Caspase 3
Inhibitory Concentration 50
Apoptosis
Phenotype
Cell Line

Keywords

  • BMS-754807
  • Combination therapy
  • IGF-1R
  • Nab-paclitaxel
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. / Awasthi, Niranjan; Scire, Emily; Monahan, Sheena; Grojean, Meghan; Zhang, Eric; Schwarz, Margaret A.; Schwarz, Roderich E.

In: Oncotarget, Vol. 7, No. 30, 2016, p. 46988-47001.

Research output: Contribution to journalArticle

Awasthi, Niranjan ; Scire, Emily ; Monahan, Sheena ; Grojean, Meghan ; Zhang, Eric ; Schwarz, Margaret A. ; Schwarz, Roderich E. / Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. In: Oncotarget. 2016 ; Vol. 7, No. 30. pp. 46988-47001.
@article{dc041eb0726a4e469f8a6e36d5a2cb75,
title = "Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models",
abstract = "Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel response by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in preclinical PDAC models. In subcutaneous xenografts using AsPC-1 cells, average net tumor growth in different therapy groups was 248.3 mm3 in controls, 42.4 mm3 after nab-paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 0.01) and 1.9 mm3 after nab-paclitaxel plus BMS-754807 (p = 0.0002). In subcutaneous xenografts using Panc-1 cells, average net tumor growth in different therapy groups was: 294.3 mm3 in controls, 23.1 mm3 after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS- 754807 (p = 0.02) and -87.4 mm3 (tumor regression) after nab-paclitaxel plus BMS- 754807 (p = 0.0001). In peritoneal dissemination model using AsPC-1 cells, median animal survival was increased compared to controls (21 days) after therapy with nab-paclitaxel (40 days, a 90{\%} increase, p = 0.002), BMS-754807 (27 days, a 29{\%} increase, p = 0.01) and nab-paclitaxel plus BMS-754807 (47 days, a 124{\%} increase, p = 0.005), respectively. Decrease in proliferation and increase in apoptosis by nabpaclitaxel and BMS-754807 therapy correlated with their in vivo antitumor activity. In vitro analysis revealed that the addition of IC25 dose of BMS-754807 decreased the nab-paclitaxel IC50 of PDAC cell lines. BMS-754807 therapy decreased phospho-IGF- 1R/IR and phospho-AKT expression, and increased cleavage of caspase-3 and PARP-1. These results support the potential of BMS-754807 in combination with nab-paclitaxel as an effective targeting option for pancreatic cancer therapy.",
keywords = "BMS-754807, Combination therapy, IGF-1R, Nab-paclitaxel, Pancreatic cancer",
author = "Niranjan Awasthi and Emily Scire and Sheena Monahan and Meghan Grojean and Eric Zhang and Schwarz, {Margaret A.} and Schwarz, {Roderich E.}",
year = "2016",
doi = "10.18632/oncotarget.9029",
language = "English (US)",
volume = "7",
pages = "46988--47001",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "30",

}

TY - JOUR

T1 - Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models

AU - Awasthi, Niranjan

AU - Scire, Emily

AU - Monahan, Sheena

AU - Grojean, Meghan

AU - Zhang, Eric

AU - Schwarz, Margaret A.

AU - Schwarz, Roderich E.

PY - 2016

Y1 - 2016

N2 - Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel response by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in preclinical PDAC models. In subcutaneous xenografts using AsPC-1 cells, average net tumor growth in different therapy groups was 248.3 mm3 in controls, 42.4 mm3 after nab-paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 0.01) and 1.9 mm3 after nab-paclitaxel plus BMS-754807 (p = 0.0002). In subcutaneous xenografts using Panc-1 cells, average net tumor growth in different therapy groups was: 294.3 mm3 in controls, 23.1 mm3 after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS- 754807 (p = 0.02) and -87.4 mm3 (tumor regression) after nab-paclitaxel plus BMS- 754807 (p = 0.0001). In peritoneal dissemination model using AsPC-1 cells, median animal survival was increased compared to controls (21 days) after therapy with nab-paclitaxel (40 days, a 90% increase, p = 0.002), BMS-754807 (27 days, a 29% increase, p = 0.01) and nab-paclitaxel plus BMS-754807 (47 days, a 124% increase, p = 0.005), respectively. Decrease in proliferation and increase in apoptosis by nabpaclitaxel and BMS-754807 therapy correlated with their in vivo antitumor activity. In vitro analysis revealed that the addition of IC25 dose of BMS-754807 decreased the nab-paclitaxel IC50 of PDAC cell lines. BMS-754807 therapy decreased phospho-IGF- 1R/IR and phospho-AKT expression, and increased cleavage of caspase-3 and PARP-1. These results support the potential of BMS-754807 in combination with nab-paclitaxel as an effective targeting option for pancreatic cancer therapy.

AB - Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel response by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in preclinical PDAC models. In subcutaneous xenografts using AsPC-1 cells, average net tumor growth in different therapy groups was 248.3 mm3 in controls, 42.4 mm3 after nab-paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 0.01) and 1.9 mm3 after nab-paclitaxel plus BMS-754807 (p = 0.0002). In subcutaneous xenografts using Panc-1 cells, average net tumor growth in different therapy groups was: 294.3 mm3 in controls, 23.1 mm3 after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS- 754807 (p = 0.02) and -87.4 mm3 (tumor regression) after nab-paclitaxel plus BMS- 754807 (p = 0.0001). In peritoneal dissemination model using AsPC-1 cells, median animal survival was increased compared to controls (21 days) after therapy with nab-paclitaxel (40 days, a 90% increase, p = 0.002), BMS-754807 (27 days, a 29% increase, p = 0.01) and nab-paclitaxel plus BMS-754807 (47 days, a 124% increase, p = 0.005), respectively. Decrease in proliferation and increase in apoptosis by nabpaclitaxel and BMS-754807 therapy correlated with their in vivo antitumor activity. In vitro analysis revealed that the addition of IC25 dose of BMS-754807 decreased the nab-paclitaxel IC50 of PDAC cell lines. BMS-754807 therapy decreased phospho-IGF- 1R/IR and phospho-AKT expression, and increased cleavage of caspase-3 and PARP-1. These results support the potential of BMS-754807 in combination with nab-paclitaxel as an effective targeting option for pancreatic cancer therapy.

KW - BMS-754807

KW - Combination therapy

KW - IGF-1R

KW - Nab-paclitaxel

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84982815653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982815653&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9029

DO - 10.18632/oncotarget.9029

M3 - Article

C2 - 27127884

AN - SCOPUS:84982815653

VL - 7

SP - 46988

EP - 47001

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -